Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ATG-031 |
| Synonyms | |
| Therapy Description |
ATG-031 is a monoclonal antibody targeting CD24, which potentially enhances antitumor immune response and decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): 6641). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ATG-031 | ATG 031|ATG031 | CD24 Antibody 3 | ATG-031 is a monoclonal antibody targeting CD24, which potentially enhances antitumor immune response and decreases tumor growth (Cancer Res (2023) 83 (7_Supplement): 6641). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06028373 | Phase I | ATG-031 | A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas | Recruiting | USA | 0 |